ZIOP ZIOPHARM Oncology Inc

2.63
0  0%
Previous Close 2.63
Open 2.6
52 Week Low 2.06
52 Week High 5.95
Market Cap $566,831,831
Shares 215,525,411
Float 208,022,592
Enterprise Value $482,181,101
Volume 1,403,909
Av. Daily Volume 1,718,720
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Ad-RTS-hIL-12 plus veledimex plus LIBTAYO (cemiplimab)
Refractory glioblastoma multiforme (GBM)
Phase 2
Phase 2
Phase 2 completion of enrolment announced June 22, 2020. Data presented at ANO November 2020.
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)
Refractory glioblastoma multiforme (GBM)
Phase 1
Phase 1
Phase 1 interim data at ASCO noted mOS has not been reached, with mean follow-up at 8.3 months.
RPM CD19-mbIL15-CAR-T cells
CD19+ leukemias and lymphomas
Phase 1
Phase 1
Phase 1 initiation announced April 19, 2021.
Sleeping Beauty - Library TCR-T
Solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 trial to be initiated 1H 2021.
Sleeping Beauty - Personalized TCR-T Program
CD19+ leukemias and lymphomas
Phase 1
Phase 1
Phase 2 trial to be initiated 2H 2021.
Sleeping beauty - TCR-T cell therapy
Solid tumors
Phase 2
Phase 2
Phase 2 enrollment has been delayed due to COVID and NIH requirements - noted November 5, 2020.

Latest News

  1. BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:

    The Jefferies Virtual Healthcare Conference, taking place June 1-4, 2021: Interim Chief Executive Officer Heidi Hagen and Chief Medical Officer Raffaele Baffa will participate in a fireside chat on June 4 at 1pm ET.

    The Virtual Raymond James Human Health Innovations Conference, taking place June 21-23, 2021: Interim Chief Executive Officer Heidi Hagen will participate in a fireside chat on June 22 at 2:40pm ET.

    Webcasts of the conference presentations…

    BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:

    The Jefferies Virtual Healthcare Conference, taking place June 1-4, 2021: Interim Chief Executive Officer Heidi Hagen and Chief Medical Officer Raffaele Baffa will participate in a fireside chat on June 4 at 1pm ET.

    The Virtual Raymond James Human Health Innovations Conference, taking place June 21-23, 2021: Interim Chief Executive Officer Heidi Hagen will participate in a fireside chat on June 22 at 2:40pm ET.

    Webcasts of the conference presentations will be available using links that will be posted on the Ziopharm website, www.ziopharm.com, in the Investor section.

    About Ziopharm Oncology, Inc.

    Ziopharm is a clinical stage biotech, developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with cancer each year. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, and a rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with leading public and private institutions including the National Cancer Institute and the University of Texas MD Anderson Cancer Center. For more information, please visit www.ziopharm.com.

    Investor Relations Contact:

    Adam D. Levy, Ph.D., MBA

    EVP, Investor Relations and Corporate Communications

    T: 508.552.9255

    E: 



    Primary Logo

    View Full Article Hide Full Article
  2. – Highlighted distinctive cellular therapy program, market opportunity and value proposition

    Shared optimistic outlook and commitment to deliver value to shareholders

    Encouraged by overwhelming vote of shareholders in favor of the Company proposals on all matters

    BOSTON, May 19, 2021 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team. In addition, shareholders approved all of the Company's proposals presented at the meeting.

    Results of Proxy Voting

    • The proposal to elect Christopher Bowden, Heidi Hagen, James Huang, Robert W. Postma, Mary Thistle…

    – Highlighted distinctive cellular therapy program, market opportunity and value proposition

    Shared optimistic outlook and commitment to deliver value to shareholders

    Encouraged by overwhelming vote of shareholders in favor of the Company proposals on all matters

    BOSTON, May 19, 2021 (GLOBE NEWSWIRE) --  Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team. In addition, shareholders approved all of the Company's proposals presented at the meeting.

    Results of Proxy Voting

    • The proposal to elect Christopher Bowden, Heidi Hagen, James Huang, Robert W. Postma, Mary Thistle, Jaime Vieser, and Holger Weis as Company directors was carried.



    • The selection of RSM US LLP as the Company's independent registered public accounting firm for the 2021 fiscal year was ratified.



    • The resolution concerning the advisory vote on the executive compensation of the Company's named executive officers was approved.



    • The amendment to the Company's amended and restated certificate of incorporation to increase the authorized number of shares of common stock was approved.

    Remarks by Interim Chief Executive Officer Heidi Hagen

    Heidi Hagen, Interim Chief Executive Offer, provided a set of remarks laying out the progress the Company has made in the past six months, a bold vision for delivering shareholder value, and broader perspectives on the commercial prospects of the Company's two key investigational cellular therapies.

    Ms. Hagen commented during the meeting, "This is a different company than it was when we met a year ago and more importantly, this is a different company than it was six months ago. We are convinced of that. We are building off a strong legacy of scientific innovation that we continue to grow, and pivoting to a more commercially-focused, clinical stage, operational Company, with clear objectives and priorities."

    Ms. Hagen also remarked on the belief in the market and commercial opportunity of the Company's two key investigational programs, its CD19 RPM CAR-T therapy, currently in a Phase I trial being conducted by the Company's Joint Venture partner, Eden BioCell, and its TCR-T Library therapy, currently in a Phase I/II trial being conducted at MD Anderson.

    Regarding the Company's CD19 RPM CAR-T therapy, Ms. Hagen commented, "It is well documented that the existing CD19 companies and therapies are ‘curative' and scientifically groundbreaking, which is why KITE and JUNO sold for a combined price of more than $20 billion. However, the cost and complexity of these current products is way too high and the commercial introduction and performance of these first generation CD19 CAR-T therapies have not been able to overcome these challenges.

    The real need in the market is to have the therapy available at a fraction of the cost to patients, while lowering the complexity to eventually allow for better patient access through treatment in any city hospital or even an oncologist's office. Our Sleeping Beauty / membrane bound IL15 platform, we believe, addresses these challenges. This combination has the potential to be administered to patients without lymphodepletion, in a matter of days, in a local setting and at a more accessible cost."

    Regarding the Company's Library TCR-T therapy and Phase I/II trial, Ms. Hagen commented, "Our current TCR hotspot library could potentially cover about 100,000 new cases of solid tumor cancer a year in the US alone. And as our library grows, that growth becomes a force multiplier of the value of our technology. This is truly a foundational trial with building momentum in the development and ultimately the commercialization of a potentially transformational therapy."  

    Ms. Hagen also commented on the capital planning strategy of the Company, saying, "It is encouraging that shareholders gave overwhelming support to the Company's request to authorize additional shares. On behalf of the Board, the management team and the Company, thank you for your trust and rest assured these shares will be used judiciously."

    After the meeting, Executive Chairman of the Board, James Huang, said, "We were pleased to see the results of the voting and to have Heidi share comments on behalf of the management team and Board. I said earlier this year that we have the opportunity to build the oncology company of the future, and I am encouraged by the tremendous progress made in the past six months. Based on my experience in the sector, I believe this Company is on a clear path to delivering significant value to shareholders."

    Shareholders and other interested parties will be able to view the webcast replay beginning May 20, 2021 by visiting www.virtualshareholdermeeting.com/ZIOP2021

    About Ziopharm Oncology, Inc.

    Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program and a precisely controlled IL-12 gene therapy. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.

    Forward-Looking Statements Disclaimer

    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the potential commercial opportunity and treatment benefits of our cell therapy programs, the expected growth of our TCR-T library, the use of our authorized shares and our ability to deliver future value to shareholders. Although Ziopharm's management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Company's operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm's product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharm's intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharm's Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

    Investor Relations Contacts:

    Adam D. Levy, Ph.D., MBA

    EVP, Investor Relations and Corporate Communications

    T: 508.552.9255

    E: 



    Primary Logo

    View Full Article Hide Full Article
  3. – Annual shareholder meeting planned for May 19, 2021

    Company to host conference call today at 4:30 pm ET

    BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates. The Company will host a conference call and webcast today at 4:30 pm ET.

    Recent Corporate Highlights and Updates

    • Announced that the infusion of the first patient in the CD19-Specific Rapid Personalized Manufacturing (RPM) CAR-T Phase I Clinical Trial being conducted in Taiwan by the Company's Joint Venture partner, Eden BioCell, occurred in March.

    • Presented a poster entitled "Hotspot mutations in KRAS

    – Annual shareholder meeting planned for May 19, 2021

    Company to host conference call today at 4:30 pm ET

    BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates. The Company will host a conference call and webcast today at 4:30 pm ET.

    Recent Corporate Highlights and Updates

    • Announced that the infusion of the first patient in the CD19-Specific Rapid Personalized Manufacturing (RPM) CAR-T Phase I Clinical Trial being conducted in Taiwan by the Company's Joint Venture partner, Eden BioCell, occurred in March.



    • Presented a poster entitled "Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system" at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting.



    • Completed construction of the GMP facility in Houston with follow on activities for facility qualification and validation to take place over the summer. The Company will then qualify the manufacturing process in the facility and file an IND amendment to enable GMP manufacturing to supplement its CMO partner's capacity for the TCR-T hotspot trial.



    • Announced it is winding down its existing Controlled IL-12 clinical program. Data indicated potential clinical benefits in a variety of cancers, including recurrent glioblastoma. The Company will continue to seek a partner for this program while re-deploying resources and will explore synergies between this technology and its cell therapy programs. The Company anticipates a headcount reduction of approximately 15% related to this wind down.



    • Anticipate the closure of the CD19 RPM CAR-T Allogeneic Phase I Trial at MD Anderson Cancer Center. The trial closure is expected to occur during the second or third quarter of 2021.



    • Plans to hold its Annual Meeting of Stockholders on May 19, 2021 at 9:00 am EDT. The meeting will be held virtually. Shareholders and interested stakeholders may attend the annual meeting online using the link below. Shareholders may submit questions during the meeting and vote shares electronically during the meeting by visiting www.virtualshareholdermeeting.com/ZIOP2021

    "Our first quarter was highlighted by execution and important strategic decisions that focus our capital on our prioritized development programs," said Heidi Hagen, Chief Executive Officer of Ziopharm. "In the coming months, we are focused on delivering important milestones on our clinical trials, including our first TCR-T trial, where we plan to treat patients beginning in the second half of the year, and continued progress on the Eden BioCell CD19-specific RPM CAR-T Trial in Taiwan."

    First Quarter 2021 Financial Results

    • Research and development expenses were $13.3 million for the first quarter of 2021, compared to $12.7 million for the first quarter of 2020, primarily reflecting increase in cell therapy program costs offset by a decrease in Controlled IL-12 program costs.



    • General and administrative expenses were $8.2 million for the first quarter of 2021, compared to $6.0 million for the first quarter of 2020. The increase in general and administrative expenses is primarily due to increased employee related expenses and legal costs associated with its expanded patent portfolio.



    • Net loss for the first quarter of 2021, was $21.6 million, or $(0.10) per share, compared to a net loss of $18.3 million, or $(0.09) per share, for the first quarter of 2020.



    • Cash and cash equivalents, as of March 31, 2021 were $100.1 million.



    • Additionally, a prepayment of approximately $5.1 million remains for work to be conducted by the Company at MD Anderson under the Company's research and development agreements.

    Earnings Conference Call and Webcast

    Ziopharm will host a conference call and webcast for the investment community today, May 6, 2021, at 4:30 p.m. EDT. The conference call can be accessed by dialing 855-327-6837 (U.S. and Canada) or 631-891-4304 (International). The passcode for the conference call is 10013973. The live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company's website for approximately 90 days after the call.

    Annual Meeting of Stockholders

    Ziopharm will host its annual meeting virtually on May 19, 2021 at 9:00 am. Shareholders and interested stakeholders may attend the meeting, submit questions, and vote their shares electronically during the meeting by visiting www.virtualshareholdermeeting.com/ZIOP2021

    About Ziopharm Oncology, Inc.

    Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program and a precisely controlled IL-12 gene therapy. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.

    Forward-Looking Statements Disclaimer

    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the wind down of the Company's Controlled IL-12 clinical program, the anticipated closure of the CD19 RPM CAR-T Allogeneic Phase I Trial at MD Anderson Cancer Center, the timing of activities relating to the Company's GMP facility, and the timing of the Company's research and development programs, including the anticipated dates for enrolling patients in the Company's TCR-T clinical trial. Although Ziopharm's management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Company's operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm's product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharm's intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharm's Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

    Investor Relations Contacts:

    Adam D. Levy, Ph.D., MBA

    EVP, Investor Relations and Corporate Communications

    T: 508.552.9255

    E: 

    Media Relations Contact: 

    LifeSci Communications:

    Patrick Bursey

    T: 646.876.4932

    E: 

    ZIOPHARM Oncology, Inc 
          
    Statement of Operations 
    (unaudited) 
          
    (in thousands except per share data) 
          
      For the Three Months ended March 31, 
       2021   2020  
          
    Operating expenses:     
    Research and development $13,336  $12,706  
    General and administrative  8,227   5,954  
    Total operating expenses  21,563   18,660  
          
    Loss from operations  (21,563)  (18,660) 
          
    Other income, net  9   367  
    Net loss $(21,554) $(18,293) 
          
    Net income (loss) applicable to common stockholders $(21,554) $(18,293) 
          
    Basic and diluted net loss per share $(0.10) $(0.09) 
          
    Weighted average number of common shares outstanding used    
    to compute basic and diluted net loss per share  213,954,665   199,814,768  
          
          
          
          
          
    ZIOPHARM Oncology, Inc 
          
    Selected Balance Sheet Data 
    (unaudited) 
          
      March 31, December 31, 
       2021   2020  
          
    Cash and cash equivalents $100,056  $115,069  
    Working capital $93,749  $112,221  
    Total assets $128,472  $146,345  
    Total stockholders' equity $105,641  $123,982  



    Primary Logo

    View Full Article Hide Full Article
  4. BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discussion at the University of Pennsylvania's upcoming Cellicon Valley symposium, May 6-7, 2021.

    "I am excited to participate in this important event on behalf of Ziopharm," said Dr. Cooper. "This meeting will bring together a wide variety of leading thinkers and researchers, and I am looking forward to sharing my perspectives on Ziopharm's unique technologies."

    The panel session, entitled "Gene Delivery and Editing for Better CARs", will be moderated by Fyodor D. Urnov, PhD, Professor of Molecular…

    BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discussion at the University of Pennsylvania's upcoming Cellicon Valley symposium, May 6-7, 2021.

    "I am excited to participate in this important event on behalf of Ziopharm," said Dr. Cooper. "This meeting will bring together a wide variety of leading thinkers and researchers, and I am looking forward to sharing my perspectives on Ziopharm's unique technologies."

    The panel session, entitled "Gene Delivery and Editing for Better CARs", will be moderated by Fyodor D. Urnov, PhD, Professor of Molecular and Cell Biology, University of California at Berkley.

    Dr. Cooper's remarks will focus on the advantages of Ziopharm's cellular therapy technologies targeting solid tumors, including its proprietary non-viral gene transfer system, Sleeping Beauty.

    Interested parties may register for the event using this link. Registrants will be able to view the event beginning at 9am ET on Thursday May 6, 2021, under Conference Track 3: Pre-Clinical / Manufacturing. The live Q&A will take place at 3:30pm ET also on May 6, 2021. Dr. Cooper's slides will also be posted on the Ziopharm website in the Investors section.

    About Ziopharm Oncology, Inc.

    Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.

    Investor Relations Contact:

    Adam D. Levy, Ph.D., MBA

    EVP, Investor Relations and Corporate Communications

    T: 508.552.9255

    E: 



    Primary Logo

    View Full Article Hide Full Article
  5. BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as follows:

    Earnings Conference Call and Webcast
    Ziopharm will host a conference call and webcast for the investment community on May 6, 2021, at 4:30 p.m. EDT. The conference call can be accessed by dialing 855-327-6837 (U.S. and Canada) or 631-891-4304 (International). The passcode for the conference call is 10013973. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The…

    BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as follows:

    Earnings Conference Call and Webcast

    Ziopharm will host a conference call and webcast for the investment community on May 6, 2021, at 4:30 p.m. EDT. The conference call can be accessed by dialing 855-327-6837 (U.S. and Canada) or 631-891-4304 (International). The passcode for the conference call is 10013973. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company's website for approximately 90 days after the call.

    Annual Meeting of Stockholders

    Ziopharm will host its annual meeting virtually on May 19, 2021 at 9:00 am EDT. Shareholders and interested stakeholders may attend the meeting by visiting www.virtualshareholdermeeting.com/ZIOP2021. Shareholders can submit questions and vote their shares electronically during the meeting using the same link. 

    About Ziopharm Oncology, Inc.

    Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm's pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.

    Investor Relations Contact:

    Adam D. Levy, Ph.D., MBA

    EVP, Investor Relations and Corporate Communications

    T: 508.552.9255

    E: 



    Primary Logo

    View Full Article Hide Full Article
View All ZIOPHARM Oncology Inc News